|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Sensei Biotherapeutics, Inc. (SNSE) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
30,590,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Sensei Biotherapeutics is a biopharmaceutical company engaged in the discovery, development, and delivery of immunotherapies. Co. has developed two platforms that are designed to address resistance to immunotherapy. Co.'s TMAb (Tumor Microenvironment Activated Biologics) platform generates antibodies that block primary immune checkpoints selectively within the tumor microenvironment. Co.'s ImmunoPhage platform is an approach to cancer therapy that utilizes and combines aspects of vaccine, gene therapy, and personalized medicine approaches. Both platforms are designed to work independently or have the potential to be combined for to create powerful rational drug combinations.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
500 |
2,700 |
| Total Buy Value |
$0 |
$0 |
$425 |
$3,964 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
1 |
2 |
| Total Shares Sold |
0 |
0 |
3,441,661 |
3,441,661 |
| Total Sell Value |
$0 |
$0 |
$5,437,824 |
$5,437,824 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
1 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Colgan Erin |
CHIEF FINANCIAL OFFICER |
• – – |
2024-02-15 |
4 |
D |
$0.79 |
$2,865 |
D/D |
(3,627) |
67,462 |
|
- |
|
| Celebi John |
PRESIDENT AND CEO |
• • – |
2024-02-15 |
4 |
D |
$0.79 |
$4,654 |
D/D |
(5,891) |
105,420 |
|
- |
|
| Van Der Horst Edward |
CHIEF SCIENTIFIC OFFICER |
• – – |
2024-02-15 |
4 |
D |
$0.79 |
$2,246 |
D/D |
(2,843) |
56,070 |
|
- |
|
| Celebi John |
President and CEO |
• • – |
2023-09-11 |
4 |
B |
$0.85 |
$425 |
D/D |
500 |
111,311 |
2.73 |
- |
|
| Cambrian Biopharma Inc |
See Remarks |
• • • |
2023-07-31 |
4 |
D |
$1.26 |
$2,000,001 |
D/D |
(1,587,302) |
3,653,120 |
|
- |
|
| Peyer James |
|
• • • |
2023-07-31 |
4 |
D |
$1.26 |
$2,000,001 |
I/I |
(1,587,302) |
3,653,120 |
|
- |
|
| Humer Kristian |
Director |
– • – |
2023-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
4,466 |
8,932 |
|
- |
|
| Peyer James |
Director |
– • • |
2023-07-10 |
4 |
A |
$0.00 |
$0 |
I/I |
4,466 |
5,240,422 |
|
- |
|
| Vojta Deneen |
Director |
– • – |
2023-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
4,466 |
8,932 |
|
- |
|
| Ricks Thomas G |
Director |
– • – |
2023-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
4,466 |
8,932 |
|
- |
|
| Broder Samuel |
Director |
– • – |
2023-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
4,466 |
8,932 |
|
- |
|
| English Jessie |
Director |
– • – |
2023-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
4,466 |
8,932 |
|
- |
|
| Cambrian Biopharma Inc |
10% Owner |
– – • |
2023-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
4,466 |
5,240,422 |
|
- |
|
| Ringo William R |
Director |
– • – |
2023-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
4,466 |
23,399 |
|
- |
|
| Holmen Bob |
Director |
– • – |
2023-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
4,466 |
25,598 |
|
- |
|
| Presight Co-Invest Management, L.l.c. |
See Explanation of Responses |
– – – |
2023-06-01 |
4 |
S |
$1.58 |
$5,437,824 |
I/I |
(3,441,661) |
0 |
|
- |
|
| Presight Co-Invest Management, L.l.c. |
See Explanation of Responses |
– – – |
2023-02-23 |
4 |
B |
$1.60 |
$3,539 |
I/I |
2,200 |
2,485,923 |
0.01 |
- |
|
| Gallagher Patrick Stephen |
Chief Business Officer |
• – – |
2023-02-15 |
4 |
D |
$1.50 |
$14,075 |
D/D |
(9,383) |
34,130 |
|
- |
|
| Celebi John |
President and CEO |
• • – |
2023-02-15 |
4 |
D |
$1.50 |
$30,738 |
D/D |
(20,492) |
110,811 |
|
- |
|
| Van Der Horst Edward |
Chief Scientific Officer |
• – – |
2023-02-15 |
4 |
D |
$1.50 |
$14,288 |
D/D |
(9,525) |
52,913 |
|
- |
|
| Colgan Erin |
Chief Financial Officer |
• – – |
2023-02-15 |
4 |
D |
$1.50 |
$16,415 |
D/D |
(10,943) |
68,089 |
|
- |
|
| Colgan Erin |
Chief Financial Officer |
• – – |
2023-02-15 |
4/A |
A |
$0.00 |
$0 |
D/D |
51,346 |
79,032 |
|
- |
|
| Gallagher Patrick Stephen |
Chief Business Officer |
• – – |
2023-02-15 |
4/A |
A |
$0.00 |
$0 |
D/D |
43,513 |
43,513 |
|
- |
|
| Celebi John |
President and CEO |
• • – |
2023-02-15 |
4/A |
A |
$0.00 |
$0 |
D/D |
73,193 |
131,303 |
|
- |
|
| Colgan Erin |
Chief Financial Officer |
• – – |
2023-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
51,346 |
73,032 |
|
- |
|
177 Records found
|
|
Page 1 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
